Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis

Brunner, Jürgen; Sitzmann, Friedrich Carl

doi:10.1007/s10165-006-0520-4

Cited by 21 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another rheumatic diseases, it was suggested that erosiv arthritis was strongly associated with the presence of anti-CCP antibodies, such as non-rheumatoid arthritis [8], in patients with systemic lupus erythematosus, who presented with polyarthritis [28] and in juvenil idiopathic arthritis [29]. We also found that anti-CCP levels were high in patients with RA.…”

Section: Discussionmentioning

confidence: 63%

Diagnostic Utility of Anti-Cyclic Citrullinated Peptide and Anti-Modified Citrullinated Vimentin Antibodies in Rheumatoid Arthritis

Keskin¹,

İnal²,

Keskin³

et al. 2008

PPL

View full text Add to dashboard Cite

Several autoantibodies found in RA are directed to epitopes in citrullinated proteins. One of them is anti modified citrullinated vimentin (Anti-MCV). We tested the value a newly developed ELISA for the detection of antibodies against a genetically modified citrullinated vimentin (anti-MCV) in comparison with an anti-CCP based ELISA system for the diagnosis of RA. Thirty-five patients with RA (mean age; 42.6 +/- 10.87 years, mean disease duration; 9.37 +/- 3.98 years) were enrolled in this study. Twenty -five ankylosing spondylitis (mean age; 35.88 +/- 6.64 years, mean disease duration; 10.25 +/- 4.61 years), and 19 healthy subjects (mean age; 40.26 +/- 5.11 years) served as controls. Anti-CCP antibodies and Anti-MCV antibodies were measured using ELISA. In all RA patients, mean anti- CCP level was 69.07 +/- 90.43 U/ml and anti-MCV level was 665.77 +/- 1040.19 U/ml. In patients with AS, the mean anti-CCP level was 10.7 +/- 5.22 U/ml and anti-MCV level was 40.54 +/- 20.15 U/ml. In healthy controls, the mean anti-CCP level was 11.11 +/- 7.65 U/ml, anti-MCV level was 23.12 +/- 12.04 U/ml. In patients with active RA, the mean serum anti-CCP level was 100.54 +/- 98.07 U/ml and anti-MCV level was 998.74 +/- 1154.93 U/ml. In patients with inactive RA, the mean serum anti-CCP level was 8.77 +/- 1.55 U/ml and anti-MCV level was 27.59 +/- 23.10 U/ml. According to these results; In patients with RA, the mean serum anti-MCV and anti-CCP levels were significantly high compared to patients with AS and healthy controls (p=0.002, p=0.001, p=0.002, p=0.001 respectively). The mean serum anti-MCV and anti- CCP levels were significantly higher in active patients with RA than in inactive patients with RA patients (p=0.001 and p=0.001 respectively). In inactive patients with RA, the mean serum anti-MCV and anti-CCP levels were similar in patients with AS and patients (p=0.484, p=0.308, p=0.09 and p=0.222 respectively). The mean serum anti-MCV levels were correlated with DAS 28 (r=0.531, p=0.001), VAS score (r=0.332, p=0.01), ESR (r=0.458, p=0.001), serum CRP levels (r=0.568, p=0.01), serum RF levels (r=0.529, p=0.001), swollen joints number (r=0.525, p=0.001) and tender joints number (r=0.638, p=0.001). As a result; measurement of serum anti-MCV levels is useful for diagnosis of RA and combined use of anti-MCV and RF may be more useful prognostic factor than either method alone, RF and anti-CCP.

show abstract

Section: Discussionmentioning

confidence: 63%

Diagnostic Utility of Anti-Cyclic Citrullinated Peptide and Anti-Modified Citrullinated Vimentin Antibodies in Rheumatoid Arthritis

Keskin¹,

İnal²,

Keskin³

et al. 2008

PPL

View full text Add to dashboard Cite

show abstract

“…Numerous studies have shown that IgM RF-positive polyarthritis patients have a higher prevalence of anti-CCP antibodies [36][37][38][39][40][41][42][43][44]45 We have also shown that the measurement of IgA, IgM, and IgG anti-CCP antibody isotypes early in the course of JIA may be beneficial to distinguish aggressive disease and possibly initiate more aggressive treatment earlier in those patients [48•]. These patients have been shown to have higher immune complex levels by the anti-Fc III method of detection and are noted to have increased disease activity [49•].…”

Section: Discussionmentioning

confidence: 99%

“…They concluded that JIA patients should not be tested routinely for anti-CCP antibodies. In another JIA study looking at anti-CCP antibodies, Brunner and Sitzmann [44] showed no statistical significance between anti-CCP antibodies and C-reactive protein or disease duration.…”

Section: Anticyclic Citrullinated Peptide Antibodiesmentioning

confidence: 97%

Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology

Syed

Gilliam²,

Moore

2008

Curr Rheumatol Rep

View full text Add to dashboard Cite

Juvenile idiopathic arthritis (JIA) is a heterogenous childhood disease without reliable biomarkers for monitoring disease progression. Immunoglobulin (Ig) M rheumatoid factor (RF) is used to define a subset of JIA patients, but its significance in JIA is dependent on the method of measurement. In addition to IgM RF, IgA RF has been implicated in determining disease severity in JIA, including functional disability and joint damage. Anticyclic citrullinated peptide (anti-CCP) antibodies have been a valuable diagnostic tool in rheumatoid arthritis, with varied results in their significance in JIA patients. Recent studies have demonstrated the possible usefulness of isotypes of anti-CCP antibodies in monitoring JIA patients to determine disease outcome. Overall, RF isotypes and anti-CCP isotypic antibodies have demonstrated increasing importance in the evaluation of JIA patients to determine which patients may have more aggressive or severe disease and to aid in possible treatment plans to prevent joint damage and disability.

show abstract

“…The presence of RF is most often seen in the polyarticular subtypes, but when present in oligoarticular patients it has been associated with early erosive disease, suggesting that an RF-positive status should be a subset of its own regardless of the number of joints involved 9. The prevalence of anti-cyclic citrullinated peptide (CCP) antibodies varies in polyarticular JIA but usually coincides with RF status 10. However, the results of a single study indicated that approximately 6% of RF-negative patients were also CCP positive and tended to be phenotypically and genetically different from RF-positive, CCP-positive patients, prompting the discussion for the need to reclassify patients not only on RF status but CCP status as well 11.…”

Section: Classificationmentioning

confidence: 99%

Polyarticular juvenile idiopathic arthritis – epidemiology and management approaches

Oberle

Harris

Verbsky

2014

CLEP

View full text Add to dashboard Cite

Juvenile idiopathic arthritis (JIA) is a group of disorders characterized by arthritis persisting for at least 6 weeks with onset before the age of 16 years. Within this cluster of conditions, the polyarticular form (involving more than four joints within the first 6 months) is further divided based on the presence of rheumatoid factor. Children with polyarticular JIA pose unique diagnostic and therapeutic challenges compared to children with involvement of fewer joints. Polyarticular JIA patients tend to have a more refractory course and therefore are at increased risk for joint damage, resulting in poorer functional outcomes and decreased quality of life. Although the ability to treat this disorder continues to improve, especially with the advent of biologic agents, there is still much about the epidemiology and pathogenesis of polyarticular JIA that is unknown. The epidemiology of polyarticular JIA varies worldwide with a vast difference in reported cases between different global regions as well as within individual countries. Several genetic risk loci have been identified conferring increased susceptibility to JIA, many within the human leukocyte antigen region. Beyond the genome, environmental factors also seem to contribute to the etiology of polyarticular JIA. This review article will focus on the epidemiology and current treatments of polyarticular JIA and briefly discuss genetic and environmental influences on the pathogenesis of JIA as well as new and emerging therapies.

show abstract

Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis

Cited by 21 publications

References 11 publications

Diagnostic Utility of Anti-Cyclic Citrullinated Peptide and Anti-Modified Citrullinated Vimentin Antibodies in Rheumatoid Arthritis

Diagnostic Utility of Anti-Cyclic Citrullinated Peptide and Anti-Modified Citrullinated Vimentin Antibodies in Rheumatoid Arthritis

Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology

Polyarticular juvenile idiopathic arthritis – epidemiology and management approaches

Contact Info

Product

Resources

About

Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis

Cited by 21 publications

References 11 publications

Diagnostic Utility of Anti-Cyclic Citrullinated Peptide and Anti-Modified Citrullinated Vimentin Antibodies in Rheumatoid Arthritis

Diagnostic Utility of Anti-Cyclic Citrullinated Peptide and Anti-Modified Citrullinated Vimentin Antibodies in Rheumatoid Arthritis

Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology

Polyarticular juvenile idiopathic arthritis &ndash; epidemiology and management approaches

Contact Info

Product

Resources

About

Polyarticular juvenile idiopathic arthritis – epidemiology and management approaches